Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Eli Lilly and Company
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Clearview Cancer Institute | Huntsville, Alabama, United States | Recruiting |
| Infirmary Cancer Care | Mobile, Alabama, United States | Suspended |
| City of Hope, Phoenix | Phoenix, Arizona, United States | Not Yet Recruiting |
| The University of Arizona Cancer Center - North Campus | Tucson, Arizona, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Los Angeles, California, United States | Not Yet Recruiting |
| Profound Research LLC | Oceanside, California, United States | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange, California, United States | Not Yet Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| Kaiser Permanente San Diego Mission Road | San Diego, California, United States | Recruiting |
| BASS Cancer Center | Walnut Creek, California, United States | Recruiting |
| Hartford Hospital (HH) | Hartford, Connecticut, United States | Recruiting |
+ 354 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06890598